首页|临床药师参与1例肺部感染患者血小板减少的病例分析

临床药师参与1例肺部感染患者血小板减少的病例分析

扫码查看
临床药师参与1例肺部感染患者血小板减少的会诊,分析患者血小板减少的可能原因.临床药师分析发现该患者血小板减少可能与感染,尤其是新型冠状病毒感染密切相关;也可能与抗感染药物头孢哌酮钠舒巴坦钠相关,氯吡格雷也不能排除.建议使用升血小板药物对症处理,停用头孢哌酮钠舒巴坦钠,氯吡格雷在密切监测下继续使用,最终患者血小板恢复正常.对于血小板减少,医务工作者应引起重视并尽快寻找可能的所有原因.若疑与药物有关,临床药师应积极配合医师,给出相应的处理方案.
Clinical pharmacist participating in the analysis of thrombocytopenia in a patient with pulmonary infection
Clinical pharmacists participated in the consultation on thrombocytopenia for a patient with pulmonary infection,and determined the possible causes.After the analysis,clinical pharmacists found that thrombocytopenia in the patient might be closely related to infection,especially COVID-19 infection.An anti-infection drug cefoperazone sodium and sulbactam sodium was a possible factor for thrombocytopenia.What's more,clopidogrel tablets might not be excluded.Clinical pharmacists suggested the patient should be treated with platelet-raising drugs.Clopidogrel may continue under close monitoring,while cefoperazone sodium and sulbactam sodium should be stopped.The platelets levels returned to normal finally.Medical workers should try to determine the various causes of thrombocytopenia.When drug adverse reactions were doubted,clinical pharmacists need to cooperate with physicians in deciding on treatment plan.

pulmonary infectionthrombocytopeniaCOVID-19adverse drug reaction

李海滨、龚卫静

展开 >

荆门市中心医院药学部,湖北 荆门 448000

华中科技大学同济医学院附属协和医院药学部,武汉 430022

肺部感染 血小板减少 新型冠状病毒感染 药物不良反应

国家自然科学基金项目湖北省自然科学基金项目

820038682020CFB388

2024

中南药学
湖南省药学会

中南药学

CSTPCD
影响因子:0.736
ISSN:1672-2981
年,卷(期):2024.22(1)
  • 5